clinical trial · NCT03992196
A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome
UCB Biopharma SRL·phase3·terminated·n = 10
Restless Legs SyndromeRotigotine 1 mg/24 hRotigotine 2 mg/24 hRotigotine 3 mg/24 h
brief summary
The purpose of this study is to assess the long-term safety, tolerability and the long-term efficacy of rotigotine treatment in adolescents with idiopathic Restless Legs Syndrome (RLS).
started
Dec 3, 2019
primary completion
Sep 1, 2022
completion
Sep 1, 2022
last updated
Oct 30, 2023
official title
A Remote, Open-Label, Long-Term, Follow-up Study to Determine the Safety, Tolerability, and Efficacy of Rotigotine Transdermal System as Monotherapy in Adolescents With Restless Legs Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol